BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21098645)

  • 1. Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells.
    Zhang H; Tolonen A; Rousu T; Hirvonen J; Finel M
    Drug Metab Dispos; 2011 Mar; 39(3):456-64. PubMed ID: 21098645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells.
    Siissalo S; Zhang H; Stilgenbauer E; Kaukonen AM; Hirvonen J; Finel M
    Drug Metab Dispos; 2008 Nov; 36(11):2331-6. PubMed ID: 18694909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucuronidation of zearalenone, zeranol and four metabolites in vitro: formation of glucuronides by various microsomes and human UDP-glucuronosyltransferase isoforms.
    Pfeiffer E; Hildebrand A; Mikula H; Metzler M
    Mol Nutr Food Res; 2010 Oct; 54(10):1468-76. PubMed ID: 20397195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms.
    Zhu L; Ge G; Zhang H; Liu H; He G; Liang S; Zhang Y; Fang Z; Dong P; Finel M; Yang L
    Drug Metab Dispos; 2012 Mar; 40(3):529-38. PubMed ID: 22180045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay.
    Di Marco A; D'Antoni M; Attaccalite S; Carotenuto P; Laufer R
    Drug Metab Dispos; 2005 Jun; 33(6):812-9. PubMed ID: 15788539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.
    Fisher MB; Campanale K; Ackermann BL; VandenBranden M; Wrighton SA
    Drug Metab Dispos; 2000 May; 28(5):560-6. PubMed ID: 10772635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
    Hanioka N; Naito T; Narimatsu S
    Chemosphere; 2008 Dec; 74(1):33-6. PubMed ID: 18990428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
    Kaji H; Kume T
    Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucuronosyltransferase isoforms.
    Al-Zoughool M; Talaska G
    J Appl Toxicol; 2006; 26(6):524-32. PubMed ID: 17080401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7.
    Bowalgaha K; Elliot DJ; Mackenzie PI; Knights KM; Miners JO
    Drug Metab Dispos; 2007 Mar; 35(3):363-70. PubMed ID: 17151189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4.
    Aprile S; Del Grosso E; Grosa G
    Drug Metab Dispos; 2010 Jul; 38(7):1141-6. PubMed ID: 20375181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol.
    Chen M; LeDuc B; Kerr S; Howe D; Williams DA
    Drug Metab Dispos; 2010 Mar; 38(3):368-75. PubMed ID: 20008037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.
    Hoehle SI; Pfeiffer E; Metzler M
    Mol Nutr Food Res; 2007 Aug; 51(8):932-8. PubMed ID: 17628876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.
    Uchaipichat V; Mackenzie PI; Guo XH; Gardner-Stephen D; Galetin A; Houston JB; Miners JO
    Drug Metab Dispos; 2004 Apr; 32(4):413-23. PubMed ID: 15039294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
    Rowland A; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
    Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC
    Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
    Cubitt HE; Houston JB; Galetin A
    Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.